Nanologica is attending the Drug Delivery to the Lungs conference (DDL) during Dec 9-11. The DDL is the premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery. The focus is on providing a forum to present t recent developments in the field of inhalation therapy. Representing Nanologica is Prof. Adam Feiler, CTO.
The publication “Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS” has been published in Nature Research Scientific Reports, Nov 26, 2020. The publication relates to Nanologica’s patent application “Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia” that became public on Oct. 15, and demonstrates how empty porous silica particles has the potential of delaying the disease progression and extending
Today at approximately 15.20, CEO Andreas Bhagwani will present Nanologica at Erik Penser Bank Company Day. The presentation can be followed live here. For more information and schedule of presenting companies, please visit Erik Penser Bank.
Nov 23-26, Nanologica will take part of the Biotechgate Digital Partnering event. This is a virtual business development event during four days with the aim of partnering and establishing new global connections. The Biotechgate Digital Partnering is designed to support the business development of Biotech, Medtech and Pharma companies through pre-booked one-on-one meetings.
Nov 18-19 marks the kick off and take off dates for the newly formed Sweden Inhalation Networks. The network is constituted of a small group of scientists with a particular interest in inhaled medicines, that have explored the opportunity to form a Swedish cross disciplinary network. The aim for the network is to maintain and further grow the world class inhalation competence in Sweden. The main targets is to facilitate sharing of inhalation science and
